Clinical Trial Update: Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and safety study of the investigational cancer drug E7820 in patients with malignant solid tumors or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma

Drugs mentioned

• E7820

Snippet

Sponsor: Eisai Inc. | Conditions: Neoplasms, Lymphoma, Malignant | Phase 1 | Status: COMPLETED